ClinicalTrials.gg
RecruitingNCT06453720OPTIMISTUpdated Jan 20, 2026

Predicting IBD Treatment Outcomes With Gut Microbiome Analysis

An observational study in Inflammatory Bowel Diseases and Crohn Disease, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 19 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-20.

Primary conditionCrohn DiseaseRegistry: Inflammatory Bowel DiseasesReclassifiedWhy we changed it
Registry
Inflammatory Bowel Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Crohn Disease
Why
  1. The study's listed conditions name Crohn Disease, a narrower term within Inflammatory Bowel Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of British Columbia · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Crohn Disease by University of British Columbia — 5 open to participants now, 5 under way, none of them phase 3. Crohn Disease · University of British Columbia.

Started
2024
the only one that year
Observational
7 of 13
3 open now
Registered
10th of 13
by date

Among the 13 studies in Crohn Disease by University of British Columbia, this one is the only one that started in 2024, is one of 7 observational ones, and was the 10th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

5 of the 13 studies in Crohn Disease by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Crohn Disease by University of British Columbia, or all of them as a file.
02

Study summary

The goal of this prospective observational study is to determine if specific microbiome signatures can predict therapeutic responses in adult patients with Crohn's disease (CD), a form of inflammatory bowel disease (IBD), living in British Columbia, Canada. The main questions this study seeks to answer are:

  1. Can microbiome signatures across different sample types (fecal, intestinal washings, and intestinal epithelial biopsies) predict response to therapy in CD?
  2. How do microbiome profiles differ between active and quiescent CD and non-IBD controls?

Researchers will compare microbiome signatures in patients with active and inactive CD as well as non-IBD controls to see if there are any microbial signatures that predict response to therapy.

Participants will:

  1. Provide fecal and blood samples.
  2. Undergo intestinal washings and intestinal epithelial biopsy specimens taken during routine colonoscopy.
  3. Participate in a longitudinal follow-up over 12 months to monitor clinical, biochemical, and endoscopic responses to therapy.
Read the detailed description

Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory condition affecting the gastrointestinal (GI) tract. The study aims to evaluate microbiome profiles (bacteriome, and mycobiome) across three different sample types (fecal, intestinal washings, and intestinal epithelial biopsies) in a cohort of adult patients with Crohn's disease (CD) living in British Columbia, Canada, and investigate whether a microbial signature may predict response to IBD therapy.

Aims:

  1. Determine microbiome signatures, across different sample types, in quiescent and active disease for patients with CD living in BC, Canada.
  2. Evaluate whether fecal, mucosal, and/or intestinal epithelial biopsy microbiome signatures can predict response to therapy.

Methods

Study Design:

Phase 1: A cross-sectional pilot study to evaluate the microbiome in patients with IBD (with active and quiescent disease) and in non-IBD controls.

Primary Outcome: Compare results of microbial analyses (including bacteriome and mycobiome) across three different sample types: intestinal washings and intestinal epithelial biopsy specimens taken during colonoscopy, as well as fecal samples.

Secondary Outcomes: Investigate correlations between the microbial analyses across different sample types and disease activity in CD. Compare the difference in microbial analyses within each sample type between active and quiescent CD as well as non-IBD patients. Investigate if fecal microbiome composition and function 2 weeks after bowel preparation is comparable to pre-bowel preparation fecal microbiome in a subset of patients with CD.

Phase 2: A longitudinal observational study with a 12-month follow-up.

Primary Outcome: Identify if there are any microbial signatures that predict response to therapy in patients with active disease requiring escalated therapy, assessed clinically and biochemically after induction (12-16 weeks) and at 12 months (+/- 3 months).

Secondary Outcomes: Compare the sensitivity and specificity of microbial analyses from each sample type in predicting response to therapy.

03

Conditions studied

  • Inflammatory Bowel Diseases
  • Crohn Disease

Browse trials for

Keywords

  • IBD
  • Crohn Disease
  • Biologic Therapy
  • Immunology
  • Gastrointestinal Tract
04

In context

Crohn Disease Reclassified

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

This study's planned enrollment of 100 is below the median of 184 across 646 observational studies indexed under Crohn Disease.

Browse Crohn Disease studies →

Lead sponsor

University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Compared within Crohn Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammatory Bowel Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The investigators aim to have 75 CD patients complete phase 1 and 2, and 25 non-IBD controls to complete phase 1 only.

Patient grouping for recruitment is as follows:

  • Group 1: 25 CD in endoscopic remission (SES-CD score \<3).
  • Group 2: 25 CD with moderate to severe endoscopically active disease (SES-CD ≥ 7 or ≥ 4 for isolated ileal CD).
  • Group 3: 25 CD with mildly endoscopically active disease (SES-CD of 3-6, or 3 with isolated ileal CD).
  • Group 4: 25 age, sex-matched non-IBD controls.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

CD patients:

  • Adult patients ≥19 years old and ≤ 80 years old.
  • CD with distal small bowel and/or colonic involvement that is endoscopically assessable with colonoscopy.
  • Undergoing colonoscopy as part of routine clinical care.
  • Active or quiescent disease.
  • Active disease will be defined as a simple endoscopic score for CD (SES-CD).
  • Quiescent disease is defined as an SES-CD \<3.
  • Mild active disease will be defined as a SES-CD of 3-6, or 3 with isolated ileal CD.
  • Moderate/severe active disease will be defined as a simple endoscopic score for CD (SES-CD) ≥ 7 or ≥ 4 for isolated ileal CD.

Non-IBD controls:

  • Adult patients ≥ 19 years old and ≤ 80 years old.
  • Undergoing colonoscopy as part of colorectal screening.

Exclusion criteria

Exclusion Criteria:

CD patients:

  • Active perianal CD - defined as collection on MRI or clinically active fistula (i.e., draining fistula).
  • Proximal small bowel (defined as not endoscopically assessable by colonoscopy) or isolated upper GI CD.
  • Colectomy or Proctocolectomy.
  • Pouch, J-Pouch or Reversed pouch surgery.
  • Short Bowel Syndrome (SBS) diagnosis.
  • Antibiotics in the last 2 months for any indication.
  • Gastroenteritis or travel outside of Canada and the United States in the last month.
  • Colorectal cancer, high-grade dysplasia or a polyp ≥2cm diagnosed at baseline endoscopy.
  • Pregnant or breastfeeding.
  • Bowel resection within the preceding 4 months.
  • Primary sclerosing cholangitis.

Non-IBD controls:

  • Found to have inflammation (deemed by endoscopist) at colonoscopy.
  • History of IBD in 1st degree relative.
  • Antibiotics in the last 2 months.
  • Gastroenteritis or travel outside of Canada and the United States in the last month.
  • Pregnant or breastfeeding.
  • Previous bowel surgeries.
06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with Crohn's disease

    The study will include 75 consenting patients with Crohn's disease, varying in levels of severity depending on assigned SES-CD scoring from their gastroenterologist. These patients will be undergoing routine colonoscopy as per their normal care routine, with this study not requiring additional scheduling commitments. Blood, mucosal washing, and intestinal biopsy samples will be collected during routine colonoscopy procedure. The patient will have the option to collect a stool sample the day before their colonoscopy and bring it to their appointment. They will also receive a sample collection kit during their appointment to collect their next required stool sample in two weeks after their scope.

    Procedure: Colonoscopy

  • Patients without inflammatory bowel disease

    The study will include 25 non-IBD age and sex-matched controls to compare data alongside the CD patients. These patients will be undergoing routine colonoscopy as per their normal colon screening routine, with this study not requiring additional scheduling commitments. Blood, mucosal washing, and intestinal biopsy samples will be collected during routine colonoscopy procedure. The patient will have the option to collect a stool sample the day before their colonoscopy and bring it to their appointment. They will also receive a sample collection kit during their appointment to collect their next required stool sample in two weeks after their scope.

    Procedure: Colonoscopy

Interventions

  • ProcedureColonoscopy

    A colonoscopy will be performed as part of routine clinical care for all participants, with the study not requiring any additional scheduling commitments outside of routine care.

07

What researchers measure

Primary outcomes

  1. Compare results of microbial analyses (including bacteriome and mycobiome) across three different sample types: intestinal washings and intestinal epithelial biopsy specimens taken during colonoscopy as well as fecal samples.

    Microbial analyses that will be undertaken for each sample type are as follows: Stool: * Metagenomics (Shotgun sequencing, ITS sequencing for fungal analysis) * Metaproteomics and metabolomics (Host, microbial, and dietary protein analysis, microbial metabolite analysis) * Anaerobic culturing (Simulate gut environment, use dietary substrates to target key microbes) Biopsy specimens: * Organoid culturing (In vitro gut model analysis, epithelial-microbiome analysis, mucin production analysis) * RNA-seq, transcriptomics (Gene expression profiling analysis, disease marker identification) * Metagenomics * Metaproteomics and metabolomics Intestinal washings: * Mucin analysis (Glycoprotein analysis) * Metagenomics * Metaproteomics and metabolomics

    Time frame: 24 months

  2. In patients with active Crohn's disease, where a decision is made to escalate therapy after the index endoscopy, identify if there are any microbial signatures that predict response to therapy after induction (12 - 16 weeks).

    * Clinical Response: Defined based on changes in clinical symptoms as per standardized clinical scoring systems (SES-CD). * Biochemical Response: Assessed through C-reactive protein (CRP) levels and fecal calprotectin, two biomarkers that indicate inflammation or disease activity. The Simple Endoscopy Score for Crohn's Disease (SES-CD) is an objective clinical assessment of the severity of a patient's Crohn's disease. A higher score means more severe disease activity. The three severity classes of SES-CD scoring are as follows: * Endoscopic remission (SES-CD \<3). * Moderate to severe endoscopically active disease (SES-CD ≥ 7 or ≥ 4 for isolated ileal CD). * Mild endoscopically active disease (SES-CD of 3-6, or 3 with isolated ileal CD).

    Time frame: 24 months

  3. In patients with active Crohn's disease, where a decision is made to escalate therapy after the index endoscopy, identify if there are any microbial signatures that predict sustained response to therapy at 12 Months (+/- 3 months).

    * Clinical Response: Continuation or improvement in clinical symptoms as measured by standardized clinical scoring systems (SES-CD). * Biochemical Response: Persistent normalization or improvement in CRP levels and fecal calprotectin. * Endoscopic Response: Improvement or healing of mucosal lesions as observed during endoscopic examination, assessed by validated clinical scoring systems (SES-CD).

    Time frame: 24 months

Secondary outcomes

  1. Investigate the correlations between the microbial analyses across different sample types and disease activity in CD.

    Correlation Analysis: Statistical measures will be used to assess the strength and direction of the relationship between microbial composition in different sample types (intestine washings, intestinal biopsy, fecal samples) and disease activity in CD. Disease Activity Measures: Disease activity will be assessed using the modified Harvey-Bradshaw Index, biochemical markers (CRP, fecal calprotectin), and endoscopic findings (SES-CD).

    Time frame: 24 months

  2. Compare the difference in microbial analyses within each sample type between active and quiescent CD as well as non-IBD patients.

    Assessments: 1\. Microbial Diversity Metrics: * Alpha-diversity Metrics: * Shannon index * Inverse Simpson diversity index * Chao1 * These metrics will be used to compare microbial diversity within each sample type between active and quiescent CD patients, as well as non-IBD patients.

    Time frame: 24 months

  3. Compare the difference in microbial analyses within each sample type between active and quiescent CD as well as non-IBD patients.

    Assessments: Differential Abundance Analysis: Differential abundance analysis will be performed using generalized linear models to identify specific microbial taxa that are significantly different between active and quiescent CD patients, and non-IBD patients within each sample type.

    Time frame: 24 months

  4. Investigate, in a subset of patients with CD, if fecal microbiome composition and function 2 weeks after bowel preparation is comparable to pre-bowel preparation fecal microbiome.

    Assessments: Comparison of Microbial Composition: Beta-diversity metrics (Bray-Curtis dissimilarity, Jaccard index) and phylogenetic-dependent distance metrics (weighted and unweighted UniFrac) will be calculated, and subsequent clustering will be applied using a principal coordinate analysis (PCoA). To test for overall microbiome differences, a PERMANOVA test will be applied. The Benjamini-Hochberg method will be applied to control for the false discovery rate.

    Time frame: 24 months

  5. Investigate, in a subset of patients with CD, if fecal microbiome composition and function 2 weeks after bowel preparation is comparable to pre-bowel preparation fecal microbiome.

    Assessments: Functional Analysis: Functional profiling of the microbiome will be conducted to assess if there are any changes in the metabolic pathways and functions of the microbiome between pre- and post-bowel preparation samples in the subset of CD patients.

    Time frame: 24 months

  6. Compare the sensitivity of the microbial analyses from each sample type in their prediction of response to therapy.

    Sensitivity of Microbial Analyses: * Using predictive models developed from microbial and statistical analyses, the sensitivity of microbial analyses from each sample type will be evaluated. * Sensitivity will be reported as the proportion of true positives correctly identified by the analysis.

    Time frame: 24 months

  7. Compare the specificity of the microbial analyses from each sample type in their prediction of response to therapy.

    Specificity of Microbial Analyses: * Predictive models will also be used to evaluate the specificity of microbial analyses from each sample type. * Specificity will be reported as the proportion of true negatives correctly identified by the analysis.

    Time frame: 24 months

08

Study locations

1 of 1 sites recruiting
  • GI Research Institute
    Vancouver, British Columbia V6Z 2K5, Canada
    Recruiting
    • Pedram Tavakoli, BSc · Contact
    • Micah Ten-Pow, BSc · Contact
09

References and documents

Publications

  • Massaro CA, Meade S, Lemarie FL, Kaur G, Bressler B, Rosenfeld G, Leung Y, Williams AJ, Lunken G. Gut microbiome predictors of advanced therapy response in Crohn's disease: protocol for the OPTIMIST prospective, longitudinal, observational pilot study in Canada. BMJ Open. 2025 Mar 13;15(3):e094280. doi: 10.1136/bmjopen-2024-094280. PubMed 40082000 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jul 2026, 23 months after the start.

Of 232 non-industry observational studies under Crohn Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 101. This study's planned 23 months is below that.

Counting every sponsor, half of 305 studies reached it within 41 months; a quarter within 29 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2024
First posted
Jun 12, 2024
StartActual
Aug 1, 2024
Primary completionEst.
Jul 1, 2026
CompletionEst.
Apr 1, 2027
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06453720
Collaborators
IBD Centre of BC, GI Research Institute, Pacific Gastroenterology Associates
Responsible party
Genelle Lunken (Assistant Professor, University of British Columbia) — Principal investigator
First posted
Jun 12, 2024
Start date
Aug 1, 2024
Primary completion
Jul 1, 2026 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Jan 20, 2026

Study contacts

Fanny LeMarié, PhD
Contact
flemarie@ibdcentrebc.ca
6044414992
Mackenzie Melvin, MSc
Contact
mackenzie.melvin@ubc.ca
7788072068

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion